Cell-Based Screening to Identify Cytoprotective Compounds by Gerő, Domokos
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 7
Cell-Based Screening to Identify Cytoprotective
Compounds
Domokos Gerő
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.73172
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Domokos Gerő
Additional information is available at the end of the chapter
Abstract
Prevention of cellular injury and consequent cell death is expected to provide therapeutic 
benefit in various diseases, but with the complexity of cell damaging pathways involved, 
identification and validation of novel potential drug targets is not a trivial task. New 
drug targets are expected to take part in complex responses with wide-ranging effects 
on gene expression and cellular function and drug candidates rather modify these effects 
than act as simple agonists or antagonists to ultimately protect the cells from an injury. 
Phenotypic screening may help identify cytoprotective compounds in diseases, in which 
the lack of drug targets makes target-based approaches unfeasible. This chapter gives an 
overview of the strategy of cell-based assay development, primary screening, hit selection 
and confirmation. Considerations about the choice of small molecule compound libraries 
utilized in cell-based models are discussed as well as the use of clinical drugs for drug 
repurposing or repositioning. The choice of cell types and issues associated with cell 
culture techniques are overviewed and the most common assays and readouts are briefly 
described. Finally, the potential pitfalls of data analysis and hit selection are discussed.
Keywords: cell-based screening, high-throughput screening, cytoprotection, drug 
discovery, chemical genomics, drug target
1. Introduction
The development of small molecule therapeutics for the treatment of diseases has gone through 
various phases over the last few decades. While the number of approved drugs continuously 
increased from the 1970s till 1996, when a record number of drugs (53 drugs) was approved by 
the Center for Drug Evaluation and Research of the U.S. Food and Drug Administration (FDA), 
a decline has been observed since then with no more than 20–30 new drugs approved each year 
[1]. In the second half of the twentieth century, drug discovery saw a rise of synthetic organic 
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chemistry that made it economically feasible to produce large combinatorial libraries and biol-
ogy progressed to provide many novel drug targets with structural details that promoted both 
high-throughput screening of small molecule libraries and computer-aided drug design as 
potential methodologies to identify novel therapeutic agents. In 2000, the number of known 
human drug targets were less than 500 but with the overestimated number of human genes and 
an expected number of 5–10 drug targets per disease genes, the number of potential drug tar-
gets were estimated to lie between 5000 and 10,000 [2–4]. The number of human genes shrank to 
19,000 and the identified small molecule drug targets rose to mere 557 (549 for FDA-approved 
drugs and 8 further targets for drugs approved in the rest of the world) in 2017, while 146 addi-
tional human protein targets were curated for biological drugs [5, 6]. In fact, the number of bio-
logical drugs and respective targets increased considerably over the last 20 years: in 2000 only 
59 biological drugs (recombinant proteins and monoclonal antibodies) were introduced, while 
250 unique biological agents were available in 2016 [3, 5]. In 2002, Hopkins and Groom argued 
that only those disease-modifying genes can be used as drug targets that are druggable (contain 
domains that small molecules can bind to) and the overlap between the druggable genome and 
genes linked to diseases may be between 20 and 50% [7]. They predicted that no more than 600–
1500 small molecule drug targets existed in humans if we had 30,000 genes. With fewer genes 
than anticipated, the number of potential drug targets also decreased, which partly explains the 
lower number of new molecular entities over the last decades. Examining the new first-in-class 
drugs (compounds that modulate a novel target or biological pathway that was not targeted 
before their introduction) approved by the FDA during the first decade after 1999, Swinney 
and Anthony found that 28 of the small molecule drugs were discovered using a phenotypic 
screening approach compared to 17 drugs discovered by a target-based approach suggesting 
that phenotypic screening may be more successful because of the unbiased identification of 
drugs with new molecular mechanisms of action [8–10]. However, the discovery of a first-in-
class drug may not be simply attributed to a phenotypic screen or a target-based approach, the 
two approaches do not mutually exclude each other [11]. The launch of a new chemical entity 
often roots in a discovery that occurred one or two decades earlier and the development of a 
drug that reaches the market often involves both approaches [11]. For example, a phenotypic 
assay may be used for the discovery of a new drug target, while subsequent optimization of 
drug candidates may occur via a target-based approach, or the two strategies may be combined 
in multiple cycles during the process. The term of ‘phenotypic screening’ may be broadly used 
for all non-target-based approaches or more selectively for testing of compounds in a system-
based approach using a target-agnostic assay that monitors phenotypic changes, thus the con-
tribution of phenotypic assays may be differently interpreted in various contexts. Nonetheless, 
phenotypic screening is making a comeback in drug discovery with large pharmaceutical com-
panies like Novartis AG and GlaxoSmithKline plc admittedly promoting it, but its overall share 
remains unclear in the efforts of pharmaceutical companies and academics [12].
2. Planning a phenotypic screen
A clear plan is needed for any early drug discovery projects and a phenotypic screen is not 
an exception [13, 14]. While the steps of the drug discovery project occur in a different order 
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than in a target-based project, it is necessary to establish a clear go/no-go plan for all the steps 
(Figure 1). Since the target is unknown in the beginning of the project and there might be 
rather wide expectations about the activity of a potential cytoprotective compound, it may 
not be necessary to define cut-off values in the beginning. However, it is necessary to make 
Figure 1. Basic plans of target-based and cell-based drug discovery approaches. (A) Target-based drug discovery 
represents the standard procedure in drug discovery. (B) Cell-based phenotypic screening skips the target identification 
step in the beginning of the project. This may lead to considerable time saving, since this step is usually performed 
simultaneously with the hit optimization. (C) Drug repurposing is possible in cell-based screening projects and it may 
accelerate the drug discovery process by skipping the hit optimization and toxicology steps. Please note the changes in 
the order of the respective steps and the expectable savings.
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 estimations about the market potential of a prospective drug candidate for the disease, so 
that we can decide on the necessary steps when the costs and potential investments arise. 
Fortunately, the earliest steps (optimization of the cell-based model and the primary screen-
ing) represent relatively low cost, foreseeable expenditures. Actually, the costs of the cell-
based screening may not exceed the expenses associated with the identification of a novel 
target to start up a target-based project. Decisions can be made based on the results of the pri-
mary screen whether it is worth proceeding with a hit compound and what kind of secondary 
tests or models to be used based on the chemical nature of the compound. In general, higher 
level of flexibility is necessary during a cell-based drug discovery project than in a target-
based project due to the unforeseeable nature of the drug target. Still, apart from the cell cul-
ture model of the disease it is worth having secondary in vitro models and a well-established 
animal model of the disease planned in the beginning of the project.
Phenotypic assays may be better suited for different disease areas than target-based approaches 
but there is no clear rule about its applicability. Santos et al. analyzed the therapeutic areas 
in which new drugs appeared and found that the majority of recent innovation occurred in 
the areas of cancer and immunology, while very little progress was seen in cardiovascular 
drugs [5]. On the other hand, the annual direct costs of cardiovascular disease and stroke 
were double the amounts of cancer-associated costs ($193.1 and $88.7 billion, respectively, 
in 2011) suggesting that higher progress is expected in this area [15]. When new molecular 
entities are considered, the lag behind other areas becomes even more apparent over recent 
years: cancer, infectious diseases and nervous system disorders are the leading areas of drug 
discovery and they all precede cardiovascular diseases [16–18]. One potential explanation for 
the disproportional representation of this area is the lack of new druggable targets in cardio-
vascular diseases, whereas the new cancer drugs and anti-infective agents are new molecular 
entities, they bind to novel protein targets. The other problem may be related to the nature of 
the injury: both anti-infective agents and cancer drugs are expected to kill the cells, while in 
cardiovascular diseases the expectation is to protect the cells from a harmful injury. In most 
instances, the mechanism of cell killing involves an inhibitory effect on the target, which is 
easier to attain than a stimulatory effect, just like it is simpler to produce an antagonist than 
an agonist for a given target since various compounds may block a binding site even if they do 
not fit perfectly in the active center but only a perfect molecular match can activate the target 
[19]. Phenotypic screening may provide a solution for the difficulties of cardiovascular drug 
discovery, since it is possible to find compounds that reduce the cellular injury even in the 
absence of a known drug target [20].
Orphan diseases represent another potential area of drug discovery using cell-based assays. 
Orphan diseases are rare disorders that affect small percentage of the population and thus 
possess a limited market potential, which led to the loss of interest by pharmaceutical compa-
nies and the lack of drug treatment in the majority of cases. The definition of orphan diseases 
are somewhat questionable, since there is no exact prevalence value associated with the term 
but in most cases if a disease affects less than 1 in 1000 or 2000 people, we call it a low preva-
lence or orphan disease [21–24]. While the incidence of rare diseases is low, the European 
Organization for Rare Diseases (EURORDIS) estimates that there are 5000–7000 distinct rare 
diseases and they affect approximately 6–8% of the population of the European Union [25]. 
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The majority of these disorders are inherited diseases and drug therapy may be necessary 
throughout the lifetime that increases their market potential. Most governments have recog-
nized the disproportionality of the potential profits and the necessary investments in case of 
rare diseases and have issued legislations to promote the development of new drug therapies 
for orphan diseases [26, 27]. As most of these diseases have a disease-linked gene and the 
mutations are easily reproduced in cellular models, they may represent the most important 
target diseases for cell-based phenotypic screening. Furthermore, if we accept the prediction 
about the number of druggable targets by Hopkins and Groom [7], the logical consequence 
is that many of these diseases will not be cured by an independent molecular entity but will 
share therapeutic drugs either with other orphan diseases or with more common illnesses. 
Thus, testing clinically used compounds with a drug repurposing approach may prove suc-
cessful in many of these disorders, which reduces the overall costs of subsequent steps.
Cellular injury and cell death are the major challenges in today’s drug discovery portfolio. 
While cancer drugs are on the rise, with cell killing as the principal mechanism of action 
of drugs, cellular injury remains the major theme of scientific research. In most diseases, 
researchers focus on cellular damage and cell death and investigate the underlying mecha-
nisms that may help us understand how to interfere with the process. Unfortunately, this 
approach is not that successful in the discovery of new drug targets, but provides us with a 
multitude of cellular and animal models of various diseases [28]. These models usually allow 
only low throughput assays to be performed but may represent a good starting point for 
phenotypic screens.
In many diseases, the question arises whether reduction of the damage will be possible if 
currently there is no therapeutic drug for the disease in clinical practice. If, under experi-
mental conditions, protection of the injured cells is accomplished by gene silencing or by 
gene therapy, there will be greater chance for establishing a pharmacological intervention in 
the future since it indicates the existence of disease-linked genes. It may not be necessary to 
induce orders-of-magnitude changes or to fully suppress the expression of a disease-linked 
gene to attain cell survival benefit, because the cell fate in an injury may be modified by small 
changes in the level of interacting proteins. Also, the existence of other experimental meth-
ods (as it was the case with ischemic pre- and post-conditioning) that induce cell protection 
may indicate the existence of potential targets prior to the identification of a disease-linked 
gene. Since phenotypic screening is a target-agnostic methodology, the outcome is of primary 
importance and not the underlying mechanism.
The mechanism of cytoprotection may not be identical with the blockage of known cell death 
pathways. Apoptosis and necrosis represent the two major cell death processes and they were 
long regarded as examples of “programmed” and “unprogrammed” cell death. Distinguishing 
a clear pathway or program in the mechanism of cell death allows us to interfere with specific 
components of the process and to block the execution of the program. In this respect, cas-
pase inhibitors are the prototypical inhibitors of apoptosis [29]. However, necrosis can also be 
blocked by poly(ADP-ribose) polymerase (PARP) inhibitors and thus its unprogrammed clas-
sification is no longer valid, even if it took us longer to fully understand the process because of 
its rapid execution [30–32]. Many other regulated forms of cell death (autophagy, pyroptosis, 
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necroptosis, parthanathos and mitoptosis) have been identified and various drugs that block 
these cell-based processes played a key role in their discovery [33]. Since cell death may occur 
simultaneously via multiple pathways, our classification of the dominant cell death form may 
change over time in various diseases as we understand more details about an injury [34]. 
Understanding the key features of a disease or an injury and reproduction of these mechanis-
tic details in a cellular model may be of higher value than close mimicking the cell death pro-
cess, as the latter often represents the final steps in the damage that we have to prevent and not 
to interfere with. Interestingly, neither caspase inhibitors nor PARP inhibitors went through 
clinical trials in their originally conceived application, but paradoxically PARP inhibitors 
reached clinical practice in diseases, in which they had seemed to play a lesser role. Thus while 
PARP was discovered as the main contributor to necrotic cell death and the first PARP inhibi-
tor started a trial in ST-Elevation Myocardial Infarction (STEMI) [35], PARP inhibitors reached 
the market later as cancer drugs: currently olaparib, rucaparib and niraparib are approved for 
ovarian cancer [36, 37]. Similarly, caspase inhibitors were initially suggested to play a role as 
potential drugs in a wide array of diseases including acquired immune deficiency syndrome 
(AIDS), ischemic diseases (myocardial infarction, stroke), neurodegenerative diseases, myelo-
dysplatic syndrome and toxic liver injury [38], but clinical trials were only started in epilepsy, 
hepatitis C virus (HCV) infection and non-alcoholic steatohepatosis (NASH) and none of the 
caspase inhibitors have reached FDA approval [39–41].
3. Compounds libraries
The number of compounds used in a cell-based assay is often lower than what can be 
screened in a simple enzymatic reaction. The cell-based models are usually more complex 
and the assays typically require longer time to perform. Furthermore, the maintenance of 
a cell culture lab for high number of assays is more costly than what is needed for simple 
biochemical assays, thus it is worth considering whether the associated costs can be limited 
by testing fewer compounds. Also, the measurement results may show higher variance in 
cell-based assays than in biochemical assays and may require higher number of repeats that 
will considerably increase the expenses. Since there is limited information about the number 
of compounds that may protect the cells against an injury, we can start the screening with 
a validation set of compounds that may contain compounds that are known to reduce the 
cellular injury in that model and also include various other compounds to see the data vari-
ability. This can give us information about the expectable number of hits in larger sets of com-
pounds and help us plan the screening strategy. A reference compound that protects against 
the injury may not be available when we study a new disease model, thus we may need to 
consider the use of controls in which the injury has not been induced and introduce the use of 
positive controls in the assay once we identified drugs that protect against the injury.
A two-step procedure may be preferred in the majority of phenotypic screens: starting with 
a smaller set of compounds with higher expectable hit ratio followed by a second screen of 
larger sets of compounds that may achieve a lower hit ratio. The number of hits is higher in 
sets of compounds that mostly contain biologically active compounds than in sets of drug-like 
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molecules. It is easily understandable that drugs that interfere with biological processes defi-
nitely possess binding sites, whereas those compounds that only show resemblance to other 
compounds do not necessarily have any targets in a cell. However, many of the biologically 
active compounds may show higher level of toxicity in the cells, since their known activity 
may not be related to cytoprotection and it may increase the data variability.
Hit selection may also include two steps in cell-based screens: (1) identification of hits in the 
primary screening and (2) a secondary confirmation assay of the hit molecules. Because of the 
higher variability of the assays and measurement values, the active compounds may show 
less cytoprotection in a single measurement than their average effect, thus it is better to use 
cut-off values that allow us to select a broader set of initial hits. These compounds will include 
many false positives, which will fail to show protection in repeated tests. If we expect a hit 
ratio around 1 in 100 molecules in the primary screen, and run confirmatory tests in repeats 
(e.g. in 3–6 repeats), it gives an the assay burden of ~50% for the hit confirmation step, which 
is substantially less than running the primary screen in duplicates. In many cases, the number 
of confirmed hits will be around or below 1 in 1000 compounds tested, so the set of test com-
pounds should include a few thousand compounds in the first primary screen to produce a 
meaningful set of data. Fewer compounds may not contain protective molecules at all and the 
lack of confirmed hits often results in discontinuation of the project.
Clinical compounds can be used for initial screening efforts and a repurposing approach 
can speed up the drug discovery process. The number of drugs approved for human use is 
around 2400 in the USA and there are no more than 4000 molecular entities approved world-
wide (including the US market) [24]. There are various sets available from a few vendors that 
contain a selection of clinically used drugs and may also include other compounds that went 
through toxicology studies but failed in the clinical phases (Table 1). If multiple of these sets 
are obtained from different companies, there is usually substantial overlap in the provided 
drugs but the vendors mostly use independent sources for the drugs and various salts of the 
same compound might be included in the different sets. Another option is to use a compound 
library of biologically active drugs. In this case, the majority of the drugs will have an anno-
tated target in the cells but not all compounds will possess a binding site: for example, the 
drug target may not be expressed in the cell type in use or an anti-infective compound may 
not have a mammalian homolog. In general, these libraries mostly contain a similar number 
of potentially cytoprotective drugs as clinical libraries but there is a huge difference between 
them in the subsequent steps. Those compounds that have gone through formal toxicology 
studies, may be directly reused for other diseases, but those compounds whose toxicity have 
never been investigated will require more follow-up work.
Larger chemical libraries comprising 10,000–100,000 drugs may be screened as a second step 
following the screen of small libraries. The number of possible drug-like molecules is not 
indefinite, but it is certainly large enough to forget about testing all possible compounds. 
Virshup et al. estimated that the set of all synthetically feasible organic molecules of 500 Da 
molecular weight or less contained over 1060 structures (“the small molecule universe”) [42]. 
Depending on the disease and target tissue, it might be possible to exclude certain chemis-
tries and by using chemoinformatics filtering methods, the composition of the library might 
be limited to a set that is easier to handle [43]. A key concept is druglikeness, prediction of 
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the properties of a molecule based on the physicochemical properties of approved drugs and 
filtering the compound library according to these parameters [44]. The absorption, distribu-
tion, metabolism and excretion (ADME) of drug-like compounds may be predicted and sub-
sets of drugs can be chosen for a specific organ or disease based on these data [45]. Lipinski 
introduced his “rule of five” concept, the filtering of molecules by solubility and  permeability 
Compound library Number 
of drugs
Short description Link
NIH Clinical 
Collection
450 Compounds that have already been 
in clinical use or in clinical trials
http://www.nihclinicalcollection.com/index.
php?cPath=21
LOPAC (Library of 
pharmacologically 
active compounds)/
TocriScreen collection
1280/1120 Known receptor agonists, 
antagonists, modulators of cellular 
responses and signal transduction
http://www.sigmaaldrich.com/catalog/
ProductDetail.do?lang=en&N4=LO12
80|SIGMA&N5=SEARCH_CONCAT_
PNO|BRAND_KEY&F=SPEC
http://www.tocris.com/dispprod.
php?ItemId=5381
US Drug Collection 1140 Compounds that have reached the 
stage of clinical trials in the USA
http://www.msdiscovery.com/usdrugs.html
International Drug 
collection
240 Compounds that have reached 
the stage of clinical trials in other 
countries
http://www.msdiscovery.com/
Killer Plates 160 Compounds with known effects on 
cellular viability
http://www.msdiscovery.com/killer.html
New Prestwick 
Chemical Library
1200 Drugs that are in clinical use http://www.prestwickchemical.com
FDA Approved Drug 
Library
640 Compounds selected from 
another library of clinically used 
compounds
http://www.enzolifesciences.com/
BML-2841/fda-approved-drug-library/
Apexscreen Library 5000 Diverse compound library, 
representative set of various 
chemotypes for screening
http://www.timtec.com/apexscreen.html
Chembridge Diversity 
Library
10,000 Drug-like diverse compound 
library for screening library
http://www.chembridge.
com/screening_libraries/
diversity_libraries/#DIVERSet
Myriascreen Library 10,000 Library of drug-like diverse 
compounds
http://www.timtec.com/myriascreen-
diversity-collection.html
Actitarg-K library 6600 Library of kinase modulators and 
similar structures
http://www.timtec.com/kinase-modulators-
actitarg-k-library.html
Natural Product 
Libtrary
640 Purified natural compounds, 
products
http://www.timtec.com/natural-compound-
library.html
AMRI Diverse sample 
library
10,000 Diverse selection of ‘lead-like’ 
compounds that covers Albany 
Molecular Research Institutes’ small 
molecular compound collections
http://www.amriglobal.com/products_and_
services/products_detail_sub.cfm?prodID=1
&subServID=4&subServID2=5
Table 1. Examples of compound libraries for cell-based screening projects.
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 prediction using the following parameters: the molecular weight is less than 500 daltons, 
CLog P is less than 5, the number of H-bond donors (the sum of OHs and NHs) is less than 
5 and the number of H-bond acceptors (all nitrogen and oxygen atoms) is less than 10, that 
greatly reduces the number of potential drug-like molecules [46, 47]. This approach suggests 
that the number of drug-like molecules that we potentially use is closer to 10,000 than to a 
million drugs, since these compounds are sparsely distributed through “the small molecule 
universe” [47]. The use of a targeted library, which consists of drugs that are known to bind 
to certain types of targets and also contains highly similar molecules, is commonly used in 
chemical genomics and may prove useful in phenotypic screening, as well [43, 48].
The concentration of drugs used in cell-based screening is mostly determined by practica-
bility and not by the effective or toxic concentrations of the individual compounds. The 
majority of compound libraries supplied compounds in solution at a fixed 1 or 2 mg/ml 
concentration in the past and nowadays, compounds are offered, mostly at 10 mM concen-
tration in dimethyl sulfoxide (DMSO) [49]. The majority of the libraries are available in 96- or 
384-well microplates, deep well plates or microtube racks. To simplify processing, dilutions 
of the compounds are best prepared at the same concentration for all drugs. While it would 
make more sense to use each clinical compound at a clinically relevant, effective concentra-
tion, equimolar concentrations are used most often to simplify and speed up the dilution 
steps. Compounds are usually screened at a concentration between 1 and 10 μmol/l, which 
might present dilution problems and may cause toxicity. Since the amount of DMSO must 
be limited as much as possible, dilutions of the drugs may be prepared in water-based solu-
tions for cell-based assays and drug precipitation may occur as a result of poor water-solu-
bility during dilution. Compound libraries are usually stored at −20°C in an upright position 
and compounds may settle down in the bottom of microtubes or wells during freeze-thaw 
cycles and some of the drugs may also precipitate. As a result, the cells may be treated with 
lower concentration of drugs than expected either due to incomplete mixing or dissolution of 
drugs. Also, compounds may lose activity during freezing and thawing, or due to an oxida-
tive reaction with DMSO, which will also have various effects on the cells and may interfere 
with the assay [50]. Thus, hit compounds, if a fresh resupply is used in the confirmation 
studies, may show similar activity at a lower concentration than in the primary screen or 
even display higher activity.
Drug combinations may provide a further option to reduce the number of assays to be run 
[51, 52]. If you expect that the number of active compounds is low, you may consider pool-
ing multiple compounds and testing them in combination. The number of assay runs may be 
reduced by an order of magnitude, if 8–12 compounds are pooled and only low number of 
“hits” is expected. Re-testing of the individual compounds will be necessary for each of the 
initial hits but since the expected hit ratio is low, it may not present excessive follow-up work. 
However, potential toxicity of the compounds needs to be considered: a toxic compound can 
mask the cytoprotective effect of an active compound if the cells are simultaneously treated 
with both drugs. Thus, the number or ratio of cytotoxic drugs might be the determining factor 
whether drug pooling is possible or not in a cellular model. On the other hand, this approach 
may allow us to search for potentiating compounds in a model if the test compounds are used 
in combination with a drug that provides limited protection [20, 53, 54].
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4. Mammalian cell culture
Cell-based screening requires adaptation of cell culture techniques to higher throughput than 
what is typical in cellular assays and may present unexpected problems associated with the 
specific cell types or models [55]. The majority of these issues could have been sorted out by 
automation but the cost of robotic systems that handle cell cultivation remains extravagant. 
The first automated cell culture stations appeared in the market a decade ago, but these mon-
strous instruments remained outrageously expensive and very few units have been sold [56, 
57]. Highly complex, cell-based models often include procedures that may not be automated 
and will require manual handling for specific steps. In this case, purchasing an expensive instru-
ment that cannot fully replace the laboratory technician may increase the overall costs. Whereas 
training technicians specifically for higher throughput cell culture may be advantageous: pro-
vides flexibility, predictable costs and allows the introduction of newer models when needed.
Choosing the right cell type for the primary screen might be the key for discovering novel drugs 
or drug actions. Primary cells are often propagated for cell-based screening projects, assum-
ing that they more closely mimic the processes of the cells in whole organisms than cell lines. 
However, primary cells are usually more difficult to grow and their division potential is limited 
to a few passages, during which they may not maintain their original characteristics. Whereas 
cell lines are well-characterized, immortalized cells that are easy to maintain and can be resup-
plied at reasonable costs, if necessary. The reagent and cell maintenance costs are lower for cell 
lines, as they can be cultured in classic cell culture media and typically grow faster. Human 
cells may be better suited for drug discovery, since the potential drug targets may not have 
orthologs in other species or the dissimilarity between the representative proteins may change 
the binding of compounds to the target [5]. On the other hand, many of the cell-based models 
use non-human cells either because the preferred cell-line originates from rodents or because 
the primary cells cannot be freshly isolated from humans. Either way, choosing the best model 
is more important than the use of human cells, since it is better to loose a few hits because of the 
differences in orthologs than to identify hits in an irrelevant model. If there are multiple options 
to choose from, it is worth keeping the lower cost model for the primary screening and use the 
other cell type as secondary model to confirm the action of hit compounds [58, 59].
Assay miniaturization is necessary to reduce the costs of cell culture and the assay-associated 
expenses [60]. Although, the ultimate goal is to minimize reagent costs, the power of testing 
treatments in larger cell populations will remain high and may be preferential depending 
on the model or assay type [61, 62]. Thus, 96-well cell culture plates are often used in more 
complex assays, while 384- and 1536-well plates can be used for simple assays when the assay 
readout is expected to change considerably with the treatments. In a simple cell viability 
assay, if the cellular injury reduces the viability by 50% and we expect that our drug treat-
ment may provide a partial protection against the injury (e.g. 20% survival benefit) then the 
pipetting error and imprecision of the measurement may not allow us to downsize the assay. 
It should be noted that in cell culture, miniaturization involves a more complex adaptation of 
the cell cultivation process than proportional scaling down of the number of seeded cells and 
all the reagents. Differences in aeration and temperature fluctuations occur between the wells 
based on their respective position on a plate: typically the edges are exposed to  excessive 
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temperature changes, evaporation and better oxygenation, while the inner wells are more 
homogeneous in this respect but they do not have comparable gas exchange and the cells 
may grow slightly slower in them. As a result, the outer wells may be excluded from analysis, 
leaving only 60 wells on a 96-well plate or 308 wells on a 384-well plate, thus 5-times higher 
number of treatments might be tested on a 384-well plate.
Contamination is a major issue in cell-based screening, because of the higher throughput of assays 
and steps that may not be carried out in an aseptic environment [63–65]. Compound libraries are 
often provided in solutions that are not sterile, though the drugs are dissolved in DMSO and 
there is little chance for bacterial contamination. The dilution step of compounds may be associ-
ated with contamination risk, partly because the storage plates often use tube caps that require 
manual handling and cannot be removed by a robotic system or because the pipetting station 
used for the dilution step does not fit in a biosafety cabinet. Also, experimental devices that are 
necessary to induce cellular injury may be utilized in some models and these instruments may 
exceed the size limits of a laminar flow cabinet [59]. While contamination risk may be minimized 
by careful planning of experiments, it is often impossible to eliminate all sources of bacterial con-
taminants. If the cell cultivation procedure is longer because the cells require longer differentia-
tion steps, or the assay investigates the long-term survival of cells, the risk of contamination will 
also increase. In general, assays terminated within 3–4 h following the injury or drug treatment, 
may allow that some of the steps are carried out on the benchtop and may not require to work in 
a biosafety cabinet, since the bacterial growth becomes exponential after a lag phase and within 
this time-frame the low level of contaminants impose little risk of interfering with the assay [66]. 
However, longer exposures or assay runs requisite that all the steps are performed in a biosafety 
cabinet using sterile technique. It is essential to plan regular decontamination and sterilization of 
the instruments to avoid generating false data because of contaminants [67].
5. Assay-related issues
The readout of the screening assay that may be a viability assay or another functional test 
plays an important role in the identification of hit compounds and it is a key contributor to 
the expenses of the project. A high sensitivity, low cost assay is the obvious choice for primary 
cell-based screening of compound libraries [68, 69]. High sensitivity does not mean that we 
need to use luminescence measurements, because it is not the detection sensitivity what is 
important but the sensitive detection of the changes in cellular function or viability. A simple, 
colorimetric lactate dehydrogenase (LDH) assay may be capable to measure minor changes in 
cell viability that costly methodologies cannot detect. Reagent cost makes a huge difference if 
the number of runs is high, thus a less expensive assay may be preferable. A custom-tailored 
assay with “home-made” reagents may be a better choice than a commercial assay, depend-
ing on the model, and may save on supplies.
Specificity of the assay and the instrumentation necessary to read the plates are of similar 
importance but reproducibility and higher sensitivity may allow more flexibility in these 
parameters. Since we expect that the number of cytoprotective compounds is low in most mod-
els, it is better to have fewer false negatives and more false positives among the initial hits, thus 
Cell-Based Screening to Identify Cytoprotective Compounds
http://dx.doi.org/10.5772/intechopen.73172
155
sensitivity may overcome the limitations of specificity. Endpoint assays are typically preferred, 
since the measurement time can severely limit the number of runs in kinetic assays. If a plate is 
read for 30 min in a kinetic assay, and the endpoint measurement lasts 1 min, it will take more 
than 2 days to read 100 plates kinetically, while the endpoint measurement can be finished 
within 2 h. (And no more than 6000–8000 compounds are tested on 100 plates if 96-well plates 
are used and the outer wells are excluded.) Thus, if an endpoint assay can replace a kinetic 
read with no or little loss in sensitivity, it remains the preferred choice in cell-based screening.
Viability assays are obvious choices for identification of protective compounds in a cytotoxic 
injury and many simple assays are available to choose from [70–72]. The most commonly 
used assays depend on substrates that are converted to easily detectable products by meta-
bolic enzymes in living cells and the results are linear with the number of viable cells within 
a limited range [73–75]. The least expensive options are colorimetric or fluorescent tests that 
requisite less costly plate readers. However, assay interference is a common problem with 
these methods: many of the test compounds are colored or fluorescent substances and they 
may produce false results. The metabolic pathways or enzymes may be up or down-regulated 
in the studied injury model, thus careful selection of the assay is necessary [53, 71, 72]. 
Homogeneous assays may be preferred, since fewer steps allow less processing error, and 
easier automation, robotic integration of the assay.
Simultaneous use of multiple viability assays can help compensate for the weaknesses of indi-
vidual tests but makes the data analysis more complex [53, 58, 71]. For example, in a cellular 
injury model, when the methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay is the pri-
mary viability assay, LDH release may be used as a secondary measurement from the simul-
taneously sampled cell culture supernatant [20, 53, 71, 72]. Thus, cytoprotection (increased 
viability) will be detectable as an increased signal in the MTT assay and also as a reduced LDH 
signal (diminished cell death) in the respective supernatant sample. Whereas the simultane-
ous increase or decrease of both the MTT and LDH signals indicates a false positivity in one of 
the assays and may not be of further interest.
In cell-based assays, differences occur in the assay results depending on the respective posi-
tion of individual wells, since the activity of metabolic enzymes is affected by the tempera-
ture fluctuations, inhomogeneity of gas exchange and potential pH variations. These effects 
may affect the results considerably in many injury models and corrections may be necessary 
to compensate for their impact. But even with the best compensations, the chances to find 
protective compounds in middle or outer wells may not be equal [53]. It is worth testing, 
that with the use of a positive control compound, our assay can similarly detect protection 
in all wells of the plate. Alternatively, we may confirm that mock-treated or vehicle treated 
(negative control) wells show similar results throughout the whole plate. If the measurements 
show larger variation, it may be necessary to run measurements in duplicates. In this case, 
duplicates need to be allocated to various positions and not to neighboring wells on a plate, 
so that the average protection will be similar for all test positions [53].
Independent repeats are expected in all cell culture experiments but running cell-based 
screens repeatedly several times would unnecessarily increase the expenses [76–79]. We can 
assume that only a handful of drugs may protect the cells and the majority of the compounds 
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will have little effect in the injury model. It is unnecessary to confirm the lack of effect for 
those drugs that exert no protection. The goal of the screen is to find potentially active drugs, 
thus screening a compound library needs a single measurement, even if we use a cell-based 
assay. The primary screen will not provide necessary data to state that the initial hits exert 
significant protection, we need to confirm the protective effect of potential hit compounds in 
repeated experiments to conclude that the effect is significant [77–79].
6. Data analysis
Hit identification is the main aim of data analysis in cell-based screening and this process may 
not follow the rules of statistics to the letter. In high-throughput screening, Z-factor has been 
used as the gold standard method to analyze the assay and data set quality [80]. This method-
ology assumes that the identification of hit compounds requisite good separation of positive 
and negative controls. However, the power of this methodology was questioned later, since 
higher background or noise values are typically present in several assays, and poor signal-to-
background or signal-to-noise separation still allow the identification of “true hits” [81, 82]. 
Larger variation occurs in a cell-based assay than in biochemical assays, even so cell culture 
experiments have been successfully used to study the effects of drug treatments. Thus, the 
variable damage induced in many injury models is an acceptable feature of the experimental 
methodology but may require more flexibility during data analysis.
The ultimate goal is to identify compounds that provide protection against an injury, which 
means less damage or increased viability of the cells depending on the specific model. A 
Z-score, the number of standard deviations from the mean vehicle treated wells undergoing 
the injury, may be calculated using the whole dataset and it easily shows the outliers [83]. 
Based on the assumptions that (1) the wells treated with various ineffective drugs will show 
similar response to the vehicle-treated wells and (2) there are very few active drugs, the com-
pound-treated wells can quasi replace the negative control wells in the analysis. However, if 
the dataset shows larger variation, the Z-scores will be smaller values, thus meaningful cut-off 
values should be chosen individually for the selection of hits in each experimental model [54, 
58, 59]. Apart from the more complex procedures, like Z-score calculation, there are various 
other options to identify cytoprotective compounds. Selection of the wells, in which dimin-
ished cell death occurred, is often easier on a single plate than in a large dataset, thus it might 
be useful to establish cut-off values based on the results of each plate separately. Data may be 
categorized immediately at plate reading and the outliers can be labeled as potential hit com-
pounds or toxic molecules depending on the changes in viability. In this way, you can start 
up the hit confirmation before the completion of the primary screen, which may be preferable 
if the primary screen of a larger compound library requisites longer time.
Hit selection may be overly complex if dual or multiple readouts are used to identify active 
compounds. In the simplest case, one of the parameters is used only at a fixed cut-off value 
and the second parameter is ranked according to the activity to find the protective com-
pounds. In a cell injury model, viability values may be used for preliminary classification of 
drugs as toxic and non-toxic compounds, and the other parameter (e.g. ROS production or 
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an inflammatory signal) may be used to determine the protective effect of test compounds 
[54, 58]. Alternatively, the measurement values may be ranked separately for the individual 
parameters and cut-off Z-scores may be established for each of them. If a test compound 
performs above the cut-off values for each of the parameters, we may classify it as a hit that 
proceeds to the confirmation step. A further option is to streamline the decision making to the 
usual single parameter analysis: a new factor may be derived from the two primary measure-
ment values, and the newly generated parameter can be ranked by the Z-scoring method.
Hit confirmation is the next step, following the identification of preliminary hits [83]. This 
procedure can take the usual steps of cell culture experiments. Independent repeats are 
needed and data analysis should be performed following the generally accepted rules of in 
vitro assays [79]. If more assays are available to test the activity of potential hits, it is worth 
including them at this step as secondary assays [83]. The cellular target of confirmed hits often 
represents new challenges, since the identification may not be a straightforward process in 
many of the disease models. However, the new targets are of high value for structure activity 
relationship (SAR) analysis and may shed new light on the mechanisms of disease develop-
ment and progression.
7. Conclusion
Recent tendency in drug discovery suggests that target-based research will be complemented 
with target-agnostic approaches in the future. As opposed to classical target-based drug dis-
covery approaches phenotypic assays may be necessary to identify novel compounds that 
show activity in orphan diseases or in common medical conditions that currently lack effec-
tive therapeutics. Cell-based models are often used to study various aspects of illnesses and 
many of these may be modified for powerful tools in drug discovery. The use of these models 
for cell-based screening may allow identification of potential drug candidates and chemical 
genomics approaches can promote reverse identification of novel drug targets [84].
Acknowledgements
D.G. received funding from the People Programme (Marie Curie actions) of the European 
Union’s Seventh Framework Programme under the grant agreement number 62810.
Author details
Domokos Gerő1,2*
*Address all correspondence to: gerodomokos@yahoo.com
1 Institute of Pathophysiology, Semmelweis University Medical School, Budapest, Hungary
2 University of Exeter Medical School, Exeter, UK
Drug Discovery - Concepts to Market158
References
[1] U. S. Food and Drug Administration. Summary of NDA Approvals & Receipts, 1938 to 
the present. Available from: https://www.fda.gov/aboutfda/whatwedo/history/product-
regulation/summaryofndaapprovalsreceipts1938tothepresent/default.htm
[2] Pennisi E. Human Genome Project. And the gene number is…? Science. 2000;288(5469): 
1146-1147
[3] Drews J. Drug discovery: A historical perspective. Science. 2000;287(5460):1960-1964
[4] Ewing B, Green P. Analysis of expressed sequence tags indicates 35,000 human genes. 
Nature Genetics. 2000;25(2):232-234
[5] Santos R et al. A comprehensive map of molecular drug targets. Nature Reviews. Drug 
Discovery. 2017;16(1):19-34
[6] Chi KR. The dark side of the human genome. Nature. 2016;538(7624):275-277
[7] Hopkins AL, Groom CR. The druggable genome. Nature Reviews. Drug Discovery. 2002; 
1(9):727-730
[8] Swinney DC. Phenotypic vs. target-based drug discovery for first-in-class medicines. 
Clinical Pharmacology and Therapeutics. 2013;93(4):299-301
[9] Swinney DC, Anthony J. How were new medicines discovered? Nature Reviews. Drug 
Discovery. 2011;10(7):507-519
[10] Zheng W, Thorne N, McKew JC. Phenotypic screens as a renewed approach for drug 
discovery. Drug Discovery Today. 2013;18(21-22):1067-1073
[11] Eder J, Sedrani R, Wiesmann C. The discovery of first-in-class drugs: Origins and evolu-
tion. Nature Reviews. Drug Discovery. 2014;13(8):577-587
[12] Kotz J. Phenotypic screening, take two. Science-Business eXchange. 2012;5(15):1-3
[13] Strovel JS, Sittampalam NP, Coussens M, Hughes J, Inglese A, Kurtz A, Andalibi L, Patton C, 
Austin M, Baltezor M, Beckloff M, Weingarten M, Weir S. Early drug discovery and devel-
opment guidelines: For academic researchers, collaborators, and start-up companies. In: 
Sittampalam GS. et al., Editors. Assay Guidance Manual. Bethesda (MD): 2004. p. 3-44
[14] Hughes JP et al. Principles of early drug discovery. British Journal of Pharmacology. 
2011;162(6):1239-1249
[15] Writing Group, M et al. Executive summary: Heart disease and stroke statistics-2016 
update: A report from the American Heart Association. Circulation. 2016;133(4):447-454
[16] Kinch MS et al. Target selection for FDA-approved medicines. Drug Discovery Today. 
2015;20(7):784-789
[17] Kinch MS, Merkel J, Umlauf S. Trends in pharmaceutical targeting of clinical indica-
tions: 1930-2013. Drug Discovery Today. 2014;19(11):1682-1685
Cell-Based Screening to Identify Cytoprotective Compounds
http://dx.doi.org/10.5772/intechopen.73172
159
[18] Munos B. A forensic analysis of drug targets from 2000 through 2012. Clinical Phar-
macology and Therapeutics. 2013;94(3):407-411
[19] Rang HP. The receptor concept: Pharmacology's big idea. British Journal of Pharmacology. 
2006;147(Suppl 1):S9-16
[20] Gero D et al. Oxidant-induced cardiomyocyte injury: Identification of the cytoprotec-
tive effect of a dopamine 1 receptor agonist using a cell-based high-throughput assay. 
International Journal of Molecular Medicine. 2007;20(5):749-761
[21] Baldovino S et al. Rare diseases in Europe: From a wide to a local perspective. The Israel 
Medical Association Journal. 2016;18(6):359-363
[22] Montserrat Moliner A, Waligora J. The European union policy in the field of rare dis-
eases. Public Health Genomics. 2013;16(6):268-277
[23] Taruscio D et al. National registries of rare diseases in Europe: An overview of the cur-
rent situation and experiences. Public Health Genomics. 2015;18(1):20-25
[24] Huang R et al. The NCGC pharmaceutical collection: A comprehensive resource of clini-
cally approved drugs enabling repurposing and chemical genomics. Science Translational 
Medicine. 2011;3(80):80ps16
[25] EURORDIS: European Organisation of Rare Diseases. Rare Diseases: Understanding 
this Public Health Priority. 2005; Available from: https://www.eurordis.org/IMG/pdf/
princeps_document-EN.pdf
[26] Dharssi S et al. Review of 11 national policies for rare diseases in the context of key 
patient needs. Orphanet Journal of Rare Diseases. 2017;12(1):63
[27] Gammie T, Lu CY, Babar ZU. Access to orphan drugs: A comprehensive review of legis-
lations, regulations and policies in 35 countries. PLoS One. 2015;10(10):e0140002
[28] Horvath P et al. Screening out irrelevant cell-based models of disease. Nature Reviews. 
Drug Discovery. 2016;15(11):751-769
[29] Pronk GJ et al. Requirement of an ICE-like protease for induction of apoptosis and 
ceramide generation by REAPER. Science. 1996;271(5250):808-810
[30] Gero D, Szabo C. Poly(ADP-ribose) polymerase: A new therapeutic target? Current 
Opinion in Anaesthesiology. 2008;21(2):111-121
[31] Gero D et al. Modulation of poly(ADP-ribose) polymerase-1 (PARP-1)-mediated oxi-
dative cell injury by ring finger protein 146 (RNF146) in cardiac myocytes. Molecular 
Medicine. 2014;20:313-328
[32] Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibi-
tors. Nature Reviews. Drug Discovery. 2005;4(5):421-440
[33] Duprez L et al. Major cell death pathways at a glance. Microbes and Infection. 2009;11(13): 
1050-1062
[34] Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature. 2015; 
517(7534):311-320
Drug Discovery - Concepts to Market160
[35] Morrow DA et al. A randomized, placebo-controlled trial to evaluate the tolerability, 
safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-
ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction 
undergoing primary percutaneous coronary intervention: Results of the TIMI 37 trial. 
Journal of Thrombosis and Thrombolysis. 2009;27(4):359-364
[36] Davar D et al. Role of PARP inhibitors in cancer biology and therapy. Current Medicinal 
Chemistry. 2012;19(23):3907-3921
[37] Brown JS, Kaye SB, Yap TA. PARP inhibitors: The race is on. British Journal of Cancer. 
2016;114(7):713-715
[38] Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995; 
267(5203):1456-1462
[39] O'Brien T, Linton SD. Design of Caspase Inhibitors as Potential Clinical Agents. CRC 
Enzyme Inhibitors Series. Boca Raton: CRC Press/Taylor & Francis Group; 2009. xii 299 p
[40] Kaur H, Kumar B, Medhi B. Antiepileptic drugs in development pipeline: A recent 
update. eNeurologicalSci. 2016;4(Supplement C):42-51
[41] Linton SD. Caspase inhibitors: A pharmaceutical industry perspective. Current Topics 
in Medicinal Chemistry. 2005;5(16):1697-1717
[42] Virshup AM et al. Stochastic voyages into uncharted chemical space produce a repre-
sentative library of all possible drug-like compounds. Journal of the American Chemical 
Society. 2013;135(19):7296-7303
[43] Dandapani S et al. Selecting, acquiring, and using small molecule libraries for high-
throughput screening. Current Protocols in Chemical Biology. 2012;4:177-191
[44] Bickerton GR et al. Quantifying the chemical beauty of drugs. Nature Chemistry. 2012; 
4(2):90-98
[45] Tao L et al. Recent progresses in the exploration of machine learning methods as in-silico 
ADME prediction tools. Advanced Drug Delivery Reviews. 2015;86:83-100
[46] Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeabil-
ity. Journal of Pharmacological and Toxicological Methods. 2000;44(1):235-249
[47] Lipinski CA et al. Experimental and computational approaches to estimate solubility 
and permeability in drug discovery and development settings. Advanced Drug Delivery 
Reviews. 2001;46(1-3):3-26
[48] Downey W, Liu C, Hartigan J. Compound profiling: Size impact on primary screening 
libraries. Drug Discovery World. 2010;(Spring)
[49] Chan JA, Hueso-Rodríguez JA. Compound library management. In: Janzen WP. editor. 
High Throughput Screening: Methods and Protocols. Humana Press: Totowa, NJ; 2002 
pp. 117-127
[50] Jacob SW, Herschler R. Pharmacology of DMSO. Cryobiology. 1986;23(1):14-27
Cell-Based Screening to Identify Cytoprotective Compounds
http://dx.doi.org/10.5772/intechopen.73172
161
[51] Kainkaryam RM, Woolf PJ. Pooling in high-throughput drug screening. Current Opinion 
in Drug Discovery & Development. 2009;12(3):339-350
[52] Elkin LL et al. Just-in-time compound pooling increases primary screening capacity with-
out compromising screening quality. Journal of Biomolecular Screening. 2015;20(5):577-587
[53] Szoleczky P et al. Identification of agents that reduce renal hypoxia-reoxygenation injury 
using cell-based screening: Purine nucleosides are alternative energy sources in LLC-PK1 
cells during hypoxia. Archives of Biochemistry and Biophysics. 2012;517(1):53-70
[54] Gero D et al. Identification of pharmacological modulators of HMGB1-induced inflam-
matory response by cell-based screening. PLoS One. 2013;8(6):e65994
[55] Maddox CB, Rasmussen L, White EL. Adapting cell-based assays to the high throughput 
screening platform: Problems encountered and lessons learned. JALA Charlottesv Va. 
2008;13(3):168-173
[56] Lehmann R et al. Biomek cell workstation: A variable system for automated cell cultiva-
tion. Journal of Laboratory Automation. 2016;21(3):439-450
[57] Ozturk SS. Equipment for large-scale mammalian cell culture. Advances in Biochemical 
Engineering/Biotechnology. 2014;139:69-92
[58] Gero D et al. Cell-based screening identifies paroxetine as an inhibitor of diabetic endo-
thelial dysfunction. Diabetes. 2013;62(3):953-964
[59] Lopez-Garcia I, Gero D, Szczesny B, Szoleczky P, Olah G, Modis K, Zhang K, Gao J, Wu P, 
Sowers LC, DeWitt D, Prough DS, Szabo C. Development of a stretch-induced neu-
rotrauma model for medium-throughput screening in vitro: Identification of rifampicin 
as a neuroprotectant. Br J Pharmacol. 2018;175(2):284-300
[60] Sundberg SA. High-throughput and ultra-high-throughput screening: Solution- and 
cell-based approaches. Current Opinion in Biotechnology. 2000;11(1):47-53
[61] Maffia AM 3rd, Kariv II, Oldenburg KR. Miniaturization of a mammalian cell-based 
assay: Luciferase reporter gene readout in a 3 microliter 1536-well plate. Journal of 
Biomolecular Screening. 1999;4(3):137-142
[62] Mayr LM, Bojanic D. Novel trends in high-throughput screening. Current Opinion in 
Pharmacology. 2009;9(5):580-588
[63] Cote RJ. Aseptic technique for cell culture. Current Protocols in Cell Biology. 2001;Chapter 
1: Unit 1. 3
[64] Stacey GN. Cell culture contamination. Methods in Molecular Biology. 2011;731:79-91
[65] Phelan K, May KM. Mammalian cell tissue culture techniques. Current Protocols in 
Pharmacology. 2016;73:12.1.1-12.1.23
[66] Naveen V, Hsiao CD. NrdR transcription regulation: Global proteome analysis and its 
role in Escherichia coli viability and virulence. PLoS One. 2016;11(6):e0157165
[67] Callaway E. Contamination hits cell work. Nature. 2014;511(7511):518
Drug Discovery - Concepts to Market162
[68] Fernandes PB. Technological advances in high-throughput screening. Current Opinion 
in Chemical Biology. 1998;2(5):597-603
[69] Kelkar M, De A. Bioluminescence based in vivo screening technologies. Current Opinion 
in Pharmacology. 2012;12(5):592-600
[70] Chan GK et al. A simple high-content cell cycle assay reveals frequent discrepancies 
between cell number and ATP and MTS proliferation assays. PLOS One. 2013;8(5):e63583
[71] Modis K et al. Cytoprotective effects of adenosine and inosine in an in vitro model of 
acute tubular necrosis. British Journal of Pharmacology. 2009;158(6):1565-1578
[72] Modis K et al. Adenosine and inosine exert cytoprotective effects in an in vitro model 
of liver ischemia-reperfusion injury. International Journal of Molecular Medicine. 2013; 
31(2):437-446
[73] Prabst K et al. Basic colorimetric proliferation assays: MTT, WST, and Resazurin. Methods 
in Molecular Biology. 2017;1601:1-17
[74] Stoddart MJ. Cell viability assays: Introduction. Methods in Molecular Biology. 2011; 
740:1-6
[75] Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, Minor L. Cell 
viability assays. In: Sittampalam GS. et al., Editors. Assay Guidance Manual. Bethesda 
(MD): 2004. p. 355-385
[76] How robust are your data? Nature Cell Biology. 2009;11(6):667
[77] Curtis MJ, Abernethy DR. Advice on statistical analysis, and new journal guidance for 
experimental design and analysis. Pharmacology Research & Perspectives. 2015;3(1):e00095
[78] Curtis MJ et al. Experimental design and analysis and their reporting: New guidance for 
publication in BJP. British Journal of Pharmacology. 2015;172(14):3461-3471
[79] Lazic SE. Experimental Design for Laboratory Biologists : Maximising Information and 
Improving Reproducibility. Cambridge, United Kingdom: Cambridge University Press; 
2016. xv 412 p
[80] Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation 
and validation of high throughput screening assays. Journal of Biomolecular Screening. 
1999;4(2):67-73
[81] Shun TY et al. Identifying actives from HTS data sets: Practical approaches for the selec-
tion of an appropriate HTS data-processing method and quality control review. Journal 
of Biomolecular Screening. 2011;16(1):1-14
[82] Sui Y, Wu Z. Alternative statistical parameter for high-throughput screening assay qual-
ity assessment. Journal of Biomolecular Screening. 2007;12(2):229-234
[83] Malo N et al. Statistical practice in high-throughput screening data analysis. Nature 
Biotechnology. 2006;24(2):167-175
[84] Jones LH, Bunnage ME. Applications of chemogenomic library screening in drug dis-
covery. Nature Reviews. Drug Discovery. 2017;16(4):285-296
Cell-Based Screening to Identify Cytoprotective Compounds
http://dx.doi.org/10.5772/intechopen.73172
163

